Rexahn Pharmaceuticals (NYSEMKT:RNN): The stock price is expected to reach $ 2.75 in the short term. The number of analysts agreeing with this consensus is 2. The higher estimate for the short term price target is at $3 while the lower estimate is at $3. The standard deviation of the price stands at $0.35.
For this week, the average consensus of the company shares are rated as a Strong Buy.
On the companys insider trading activities, The Securities and Exchange Commission has divulged that Jeong Tae Heum, officer (Chief Financial Officer) of Rexahn Pharmaceuticals, Inc., had unloaded 317,272 shares at an average price of $0.91 in a transaction dated on January 8, 2015. The total value of the transaction was worth $288,718.
Rexahn Pharmaceuticals (NYSEMKT:RNN) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.0021 points or 0.77% at $0.2698 with 1,250,237 shares getting traded. Post opening the session at $0.275, the shares hit an intraday low of $0.26 and an intraday high of $0.275 and the price was in this range throughout the day. The company has a market cap of $58 million and the number of outstanding shares have been calculated to be 213,173,790 shares. The 52-week high of Rexahn Pharmaceuticals (NYSEMKT:RNN) is $0.69 and the 52-week low is $0.2502.
Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of treatments for cancer and other medical needs. The Company has three clinical stage drug candidates in active development: Archexin, a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance; RX-3117, a small molecule nucleoside compound with an anti-metabolite mechanism of action and has therapeutic potential in a range of cancers, including colon, lung and pancreatic cancer, and Supinoxin (RX-5902), a small molecule that inhibits the phosphorylation of p68, which is expressed in cancer cells, but not in normal cells, results in up-regulation of cancer-related genes and a subsequent proliferation or tumor growth of cancer cells. The Company also has two drug candidates in pre-clinical development: Archexin-Nano and RX-21101.